Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
392. lappuse
... peak at approxi- mately 280 nanometers . Determine the exact position of the absorption peak for the particular instrument used . ( b ) Cefuroxime axetil for oral suspen- sion . Using a suitable spectrophotom- eter and Sorenson's ...
... peak at approxi- mately 280 nanometers . Determine the exact position of the absorption peak for the particular instrument used . ( b ) Cefuroxime axetil for oral suspen- sion . Using a suitable spectrophotom- eter and Sorenson's ...
393. lappuse
... peak ( at a retention time equal to that observed for the standard ) in the chromatogram of the sample ; As Area of the clarithromycin peak in the chromatogram of the clarithromycin standard ; C Clarithromycin activity in the ...
... peak ( at a retention time equal to that observed for the standard ) in the chromatogram of the sample ; As Area of the clarithromycin peak in the chromatogram of the clarithromycin standard ; C Clarithromycin activity in the ...
395. lappuse
... peak at approximately 259 nanometers . Determine the exact posi- tion of the absorption peak for the par- ticular instrument used . ( v ) Calculations . Determine the per- cent of label dissolved as follows : Percent dissolved = ( Asam ...
... peak at approximately 259 nanometers . Determine the exact posi- tion of the absorption peak for the par- ticular instrument used . ( v ) Calculations . Determine the per- cent of label dissolved as follows : Percent dissolved = ( Asam ...
396. lappuse
... peak height above the baseline or the asym- metry factor ( A , ) measured at a point 10 percent of the peak height from the baseline ; whichever is required in the appropriate monograph , as follows : where : T = Woos 2f 0.05 Wo.os ...
... peak height above the baseline or the asym- metry factor ( A , ) measured at a point 10 percent of the peak height from the baseline ; whichever is required in the appropriate monograph , as follows : where : T = Woos 2f 0.05 Wo.os ...
399. lappuse
... peak . The resolution of the peaks should be complete . The elution order is : Internal standard , clindamycin , and ... peak ( at a retention time equal to that ob- served for the clindamycin standard ) / Area of internal standard peak ...
... peak . The resolution of the peaks should be complete . The elution order is : Internal standard , clindamycin , and ... peak ( at a retention time equal to that ob- served for the clindamycin standard ) / Area of internal standard peak ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning